همراهی بین پلی‌مورفیسم‌های هموزیگوت‌ متیلن تتراهیدروفولات ردوکتاز و آنتی‌ژن PLA2 پلاکتی با ترومبوآمبولی وریدی (VTE) در شهرکرد

  B. Pourgheysari[1][2], A. Hasheminia[3], H. Rouhi-Boroujeni3   Received: 20/02/2014 Sent for Revision: 22/01/2014 Received Revised Manuscript: 09/10/2012 Accepted: 28/07/2012   Background and Objective: Venous thromboembolism (VTE) is one of the main causes of mortality in different human communities. Factor V Leiden, MTHFR C677T polymorphism and PLA2 polymorphism of platelet glycoprotein IIb/IIIa are important inheritance risk factors of VTE. As limited data of homozygous factors exists, the aim of the study was to investigate the association between homozygous polymorphisms and VTE in Shahrekord. Materials and Methods: In this cross-sectional study, EDTA venous blood was taken from 72 patients with venous thromboembolism referred to Shahrekord Hajar Hospital, and 306 age and sex matched healthy volunteers. Genotyping of factor V Leiden, MTHFR C677T and PLA2 polymorphisms was done by PCR-RFLP. Statistical analysis was done using descriptive statistics and χ2 test. Results: There was a significant difference between patients and controls in the number of homozygous polymorphisms with the frequency of 16.77% and 4.90%, respectively (P=0.004). Homozygous FVL was more prevalent in patients than controls, but the difference was not significant. A significant difference was observed in the frequency of homozygous MTHFR C677T and PLA2 polymorphisms between the patients and controls (P=0.03 and P=0.001, respectively). The difference was not significant in the frequency of heterozygous polymorphisms except for PLA2. Conclusion: The results of the study show the association between homozygous MTHFR and PLA2 thrombophilia polymorphisms and VTE in Shahrekord. Acquired risk factors may need to be controlled in homozygous carriers of these polymorphisms. Homozygous VTE carriers may need to be managed differently than other patients. Key words: Venous thromboembolism, Factor V Leiden, Methylene tetrahydrofolate reductase, PLA2 polymorphism, Homozygote Funding: This work was funded by Shahrekord University of Medical Sciences (Deputy of Research) Conflict of interest: None declared. Ethical approval: Ethical permission was obtained from the Shahrekord University of Medical Sciences Ethics Committee   How to cite this article: Pourgheysari B, Hasheminia A, Rouhi-Boroujeni H. Association between homozygous Methylene Tetrahydrofolate Reductase and Platelet PLA2 Antigen Polymorphisms with Venous Thromboembolism (VTE) in Shahrekord J RafsanjanUniv Med Sci 2014 13(2): 183-92. [Farsi]   [1]- Associate Prof., Dept. of Pathology and Hematology Cellular and Molecular Research Centre, Shahrekord University of Medical Sciences, Shahrekord, Iran (Corresponding Author): Tel: 0391- 5228397, Fax: 03915228497, Email: [email protected] [2]- Academic Member Dept. of Nursing, Shahrekord University of Medical Sciences, Shahrekord, Iran [3]- Associate Prof., Dept. of Internal Medicine, Clinical Biochemistry Research Centre, Shahrekord University of Medical Sciences, Shahrekord, Iran